<i id='7B77777329'><strike id='7B77777329'><tt id='7B77777329'><pre id='7B77777329'></pre></tt></strike></i>
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel
read more
AdvocatesforpeoplewithlongCovidandmyalgicencephalomyelitis/chronicfatiguesyndromehostaninstallationo
read more
AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin
read moreMariaFabrizioforSTATThisstorycontainsdescriptionsofaninvasivemedicalprocedureandmentionofsexualassau
